U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback